Urine Monocyte Chemoattractant Protein-1(UMCP-1) as a Biomarker of Renal Involvement in Systemic Lupus Erythematosus

Document Type: Original Article

Authors

1 Rheumatic Diseases Research Centre (RDRC), Mashhad University of Medical Sciences, Mashhad, Iran

2 Immunology Research Centre (IRC), Mashhad University of Medical Sciences, Mashhad, Iran

3 Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

4 Vice Chancellor for Research Office, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Objective(s)
Lupus nephritis (LN) is frequently associated with a poor long-term prognosis. Renal biopsy is the diagnostic method of choice in this condition. Urine biomarkers have been mentioned in the diagnosis of LN. The study,s purpose was to evaluate the performance of urinary monocyte chemoattractant protein 1(UMCP-1) as a biomarker of renal involvement in systemic lupus erythematosus.
Materials and Methods
Forty-one recently diagnosed systemic lupus erythematosus patients (8 male and 33 female) without renal involvement (group 1) and twenty six patients (8 male and 18 female) with LN (group 2), proven by biopsy, were recruited to this study. UMCP-1 sensitivity and specificity for identifying biopsy-proven nephritis were calculated, and a receiver operating characteristic (ROC) curve was constructed to quantify how definitely UMCP-1 distinguishes between patients with and without LN.
Results
The mean value of UMCP-1 levels were 733.07 pg/ml ± 1282.54 and 144.16 pg/ml ± 137.90 in patients with and without LN respectively. The UMCP-1 level was significantly higher in group 2 than group 1. There was no significant correlation between UMCP-1 and 24-hour urine protein (r = 0.031, P= 0.874). The area under the ROC curve was 0.727 with a CI 95% of 0.597 to 0.857 (P=0.002). Using a cut-off value of 82 pg/ml,UMCP-1 had a sensitivity of 88.5% and a specificity of 46.3% for identifying LN.
Conclusion
UMCP-1 can serve as a biomarker of LN although further longitudinal studies of these biomarkers are required in LN.

Keywords


1. Jill P. Buyon. Systemic Lupus Erythematosus A. Clinical and Laboratory Features. In: John H. Klippel, Primer on the Rheumatic Diseases 2008.p. 303-318.
2. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited.J Am Soc Nephrol 2004 15:241-50.
3. Lec EG. Cellular interactions in the pathogenesis of lupus nephritis: the role of T cells and macrophage in the amplification of the inflammatory process in the kidney. Lupus 1998; 7: 597-603.
4. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant.Proc Natl Acad Sci U S A. 1994; 91:3652-6.
5. Kelley VR, Rovin BH. Chemokines: therapeutic targets for autoimmune and inflammatory renal disease. Springer Semin Immunopathol 2003; 24:411-421.
6. Rovin BH, Phan LT. Chemotactic factors and renal inflammation.Am J Kidney Dis 1998; 31:1065-84.
7. Tesch GH, Maifert S, Schwarting A, Rollins BJ, Kelley VR. Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas (lpr) mice. J Exp Med 1999; 190:1813-24.
8. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40:1725.
9. Wada T, Yokoyama H, Su SB, Mukaida N, Iwano M, Dohi K, et al. Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int 1996; 49:761-7.
10. Tucci M, Barnes EV, Sobel ES, Croker BP, Segal MS, Reeves WH, et al. Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthritis Rheum 2004; 50:1842-9.
11. Rovin BH, Song H, Birmingham DJ, Hebert LA, Yu CY, Nagaraja HN. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. Clin Nephrol 2004; 16:467-73
12. Liu ZJ, Lin JY. Expression of monocyte chemoattractant protein-1 and lupus nephritis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2005; 27:491-5.
13. Kiani A, Arthur J, Magder L, Laurence O, Jim C, Petri M. Lupus Nephritis: Urinary Biomarkers [abstract] Arthritis Rheum 2009; 60 Suppl 10:917.
14. Marks SD, Williams SJ, Tullus K, Sebire NJ. Glomerular expression of monocyte chemoattractant protein-1is predictive of poor renal prognosis in paediatric lupus nephritis. Nephrol Dial Transplant 2008; 23: 3521–3526.
15. Dai C, Liu Z, Zhou H, Li L. Monocyte chemoattractant protein-1 expression in renal tissue is associated with monocyte recruitment and tubulo-interstitial lesions in patients with lupus nephritis. Chinese Medical J 2001; 114: 864-868. 16. Kim HL, Lee DS, Yang SH, Lim CS, Chung JH, Kim S, et al. The polymorphism of monocyte chemoattractant protein-1 is associated with the renal disease of SLE. Am J Kidney Dis 2002; 40:1146-52.